ENPP1抗体;ENPP1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P12523(ENPP1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1) is a transmembrane enzyme that hydrolyzes extracellular nucleotides like ATP and AMP, generating inorganic pyrophosphate (PPi), a key regulator of bone mineralization and soft tissue calcification. It plays roles in phosphate metabolism, insulin signaling, and immune modulation. ENPP1 antibodies are tools used to study its expression, function, and involvement in diseases.

Mutations in ENPP1 are linked to rare genetic disorders, including autosomal recessive hypophosphatemic rickets (ARHR2) and generalized arterial calcification of infancy (GACI). ENPP1 dysregulation is also implicated in metabolic syndromes, cancer progression, and pathological calcification. Antibodies targeting ENPP1 help detect protein levels in tissues or fluids via techniques like Western blot, immunohistochemistry, or flow cytometry, aiding research on disease mechanisms.

Therapeutic anti-ENPP1 antibodies are under exploration for conditions like tumor immunotherapy, as ENPP1 overexpression in cancers suppresses anti-tumor immunity by degrading extracellular ATP, a pro-inflammatory signal. Conversely, recombinant ENPP1 or enzyme replacement strategies are being tested for ENPP1-deficient disorders. Thus, ENPP1 antibodies serve both diagnostic and therapeutic roles in understanding and managing calcification-related and metabolic diseases.